you. Well, CEO. webinar on my behalf first thank It's of Immuron as
thank both Immuron well mediated today. the joining point products, to biopharmaceutical you as click is important we So to that disease have here through commercial we company. I'll And gut first so a products. as is just here. developing note globally commercializing, integrated slide for two
$XX.X a and our long of of time million We million have of and cash as We've corporate XXrd Capitalization had as been equivalents August of refreshed around July, XXXX. XXth the market. $XX.X structure. of we the of
for to an aseculation So you and CEO Joanne increased Immuron expands we I'm seen as acquired FY rebound would today distribution addressable that, have into travel the grow recently and significantly. as continues international XXXX. travel company The again the market is capability Great and starting an sales and here news on Casey, R&D its Manager. to
a that of target capable pathogens. more a there a are words of I'll producing it, That's Essentially, orally technology to active but lot later. it's a that platform isn't little highly about allows talk bit us immunoglobulins. specific technology, We enteric
XXXX entire completing for strategy the and the presently exceeded the We’re travel. resurgence an competitive by implementing assessment shareholder in budget largely a growth by company FY portfolio, advantage view value. markets, target revenue of XX%, growth global increase to drivers, driven with to
cap financial snapshot for million, here, the strategy initiate sheet, $XX next Travelan, company. the to an IND with market an an plan cash and strong major that, see IMM-XXXE trial company and company once M&A for cash the and $XX.X. year. filed again, The balance have FDA our clinical equivalents the supports is extremely We Quick milestone this you for which grow can of to organic
undervalued be in and we fair lies. where to we'll talk say company it about are that value that more the think would I
our You can holder in see management below the U.S. the there, of the of of substantial BNY and Depository board the a shareholders, by the in American company. X% shares, roughly shares held XX% has also interest so Mellon,
with Strengths a established our of the over services but the well relationships. also the not of grow only company we're States. Australia, are in to In before, the covered. distribution network the about evidence that about Essentially, aligned wealth United pharmacies We U.S. and in we pharmacy cornerstone touch X,XXX the have shareholders I saw plan I'll that later. products. of We in in the more retail platform technology company. travel talked customer Passport the with based in OTC medicine Health, provider the largest lied
product, into gut liver second health is Protectyn and our The and which a We're plan product launch exploring network. for both that. USA to we Canada
a the addressable at have just Let's look market here.
large market market $X market digestive health Travelan is growing has is billion potential. greater large supplements in diarrhea market at So a itself of $XX it's it's and a growing. billion, a than Traveler's X%. for
billion market Clostridiodes Data. a that's of market and $XX lead and if one Global $XX U.S. respectively, to to at a XXXX Europe. U.S. looking those rate numbers, the expected XX%. million, So and The travel we in infections by clinical our has look difficile of million potential at $X.X assuming EU and sales programs this On of assumptions, we're conservative according was penetration be
experienced XX% Wouldn't flagship our diarrhea. should there product Just like touching remember traveler’s start again? on see you to of that can Travelan. traveling all to we the If we we right travelers do, XX%
take medicine traveler’s Travelan, to only for So preventative it's important the diarrhea.
at have look platform. Let's our technology quickly a just
bovine it's on colostrum. So based
bovine take from vaccine. a is allowed the that. pathogens. a cow to pathogens Australia. rich we We So of We like make targeted in a and toxins get we're clear neutralize broad it carving, is label immunize, benefits antibody and isolate we natural those specific number for highly of we what that specific hyperimmune colostrum, claims do you which lot results But a we in
So for not function defense, as Travelan, we occurrence, gastrointestinal can example, and lining. reduce we reduce repairing for as the cramping, and wall pain, relieve relief well gut immune can diarrhea, reduce gastrointestinal only liver also abdominal health,
it it can activity. a broad see broad liver has Not and target gut. it's does in pathogens, So activity you the only gut those
look a have clinical our at here. programs Let's
So there's two sections here.
of The those proud partnered We're first our and programs. quite Immuron programs. second of is partnered the programs
some Departments Government of we've got the Defense leading us. So working with
undertaking that product confirming in is Services during research infection its the we're coli sure is Clostridiodes, planning for currently trials program mentioned two a mentioned this its get and years to about seen sold technology I on opportunity in a think what the the ETEC, in We're filing and in a Protectyn. do the Travelan with that in so USA this is release. billion capability, resolve that to lot Travelan Medical as that market. challenge developed I Travelan, FDA study ahead distribution Research we and human That's we're programs Canada. armed Uniformed on IMM-XXX Center. of science selling on product clinical clinical that companies we've model and Australia, commercial and just back that have and the to Touching hoping diseases, last would the new that product the Enterotoxigenic we possible forces. we're and been for spoken the the clinical OTC of University with milestone but as for will that before, with that the both planning make it to opportunity. CampETEC on market, U.S. IND hold. products, with hold trial to Also currently before that’s well. for move to another plan ASX Travelan market So evaluation, a Unfortunately, conjunction doing already in get soon controlled check the the product $X.X market has hold that With market pandemic regards that is as you double We're underway. study Naval order soon E.
have we strengths In or have we retail presence retail have pharmacy, the In than Australian e-commerce. in the and the Canada, Health. more in market X,XXX travel BXB pharmacies. Passport US with business-to-business We largest clinic a pharmacy
Here loss profit is and a statement.
low presentation. a and includes based and Canada. was After can the that U.S. with So growing world, rest this in with see both which offer growth the you XXX% revenue of all, results Australia
of the pandemic and we'd reached good breakeven. run Back planning the margins I business million We have The strong get have rate that. non-current a recognition here. there strategy. even other organic before is to almost cash profit products side very What liability is allow both only lease grow mentioned balance us around beyond back does these $X of sheet, $XX.X pursue before The allows M&A there to this for? we and a we're and of to commitment. debt. to million and no commercial of a for an essentially It
in network are beyond marketing Australia; distribution, on looking to target commercial to only Protectyn; Travelan the we sales geographies focus products, sales growth not expand across and activities. our growing and our Canada So going U.S., products and
which a as so other can thing we We be well, at new have once-daily formulations for dosing, example, got currently expand. within approval. We're We FDA would the for channels exist the looking good markets.
secure NMRC, making on, On that IND, that to for our and cost approval customer the this -- has program. plan and that's initiate base. the coming some Keys that so up M&A synergies, growing market this focusing product trial base. and key offering, IP half sure milestones Travelan Key management, the that can our of view that program criteria to as before the and having science mentioned verticals of year. upon this as side, I our of complete two filing we're year. topline company next obviously, and product plan year. the target year or Enterotoxigenic before, earnings to in end calendar well of I and We we expanding expanding letter the and clinical revenue underway to strong for coli, IND so are planned Campylobacter that's before separate hopefully conjunction calendar product. the the with ETEC of get E. program before are that, the two we calendar clinical and that in trials half that first a for mentioned to particular CampETEC hold with There submit results The the programs of in calendar the the response end next that
that that Thank how back are trial I've clinical questions. we're those I'll end looking XXXX of beginning performs before submitting I'm Travelan, is for I this to our scientifically we that and at hand Uniformed field references and the that move I Florastor, underway. IMM-XXX, slide sure lead my shown program first This of That assuming that showing market for for year. base The trial the in for to the that risk. many manufacture commercial real one's product to well approved, University some areas of half go world you. like Clostridiodes If we'll commercial share minded. IND project It's Q&A, this well in that year, Travelan evaluation Services looking with This are mentioned key our of that before, before And XXXX. setting, and scientific here. in the concludes be drug a Q&A. products a product, high of plan you'll around important references is have a we as people last of Travelan the of the FDA next we getting have IMM-XXX for you the calendar that. an first starting On of difficile. it'll to half to evidence clinical on through the confirms trial the show presentation. as view the just to at to traveling
